Marshall Wace
GANX icon

Marshall Wace’s Gain Therapeutics GANX Stock Holding History

Marshall Wace’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9M Buy
1,923,546
+153,758
+9% +$283K ﹤0.01% 1494
2026
Q1 		$3.43M Buy
1,769,788
+107,495
+6% +$234K ﹤0.01% 1500
2025
Q4 		$5.35M Buy
1,662,293
+1,487,186
+849% +$3.97M ﹤0.01% 1121
2025
Q3 		$310K Sell
175,107
-101,326
-37% -$171K ﹤0.01% 2414
2025
Q2 		$498K Buy
276,433
+80,407
+41% +$149K ﹤0.01% 2144
2025
Q1 		$374K Buy
196,026
+104,288
+114% +$231K ﹤0.01% 2188
2024
Q4 		$198K Buy
+91,738
New +$184K ﹤0.01% 2355

Other funds holding GANX

PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace's GANX Position: Q2 2026 in Review

Marshall Wace increased its Gain Therapeutics (GANX) stake by 8.7% in Q2 2026, buying an estimated $283K and bringing the position to 1,923,546 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1494.

Marshall Wace first reported a position in GANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.35M in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Marshall Wace held 1,923,546 shares of Gain Therapeutics worth $3.9M as of Q2 2026.
  • Marshall Wace bought 153,758 Gain Therapeutics shares in Q2 2026, an estimated $283K.
  • Gain Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1494 holding.
  • Marshall Wace first reported a position in Gain Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Marshall Wace's Gain Therapeutics position peaked at $5.35M in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.